These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31496136)

  • 41. Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Raspanti A; Giacomini A; Guidi S; Emili M; Ciani E; Giuliani A; Bighinati A; Calzà L; Magistretti J; Bartesaghi R
    Neurobiol Dis; 2017 Jul; 103():11-23. PubMed ID: 28359846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Developmental excitatory-to-inhibitory GABA polarity switch is delayed in Ts65Dn mice, a genetic model of Down syndrome.
    Lysenko LV; Kim J; Madamba F; Tyrtyshnaia AA; Ruparelia A; Kleschevnikov AM
    Neurobiol Dis; 2018 Jul; 115():1-8. PubMed ID: 29550538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome.
    Contestabile A; Fila T; Cappellini A; Bartesaghi R; Ciani E
    Cell Prolif; 2009 Apr; 42(2):171-81. PubMed ID: 19317805
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The mouse model of Down syndrome Ts65Dn presents visual deficits as assessed by pattern visual evoked potentials.
    Scott-McKean JJ; Chang B; Hurd RE; Nusinowitz S; Schmidt C; Davisson MT; Costa AC
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3300-8. PubMed ID: 20130276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
    Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
    Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field.
    Coussons-Read ME; Crnic LS
    Behav Genet; 1996 Jan; 26(1):7-13. PubMed ID: 8852727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down Syndrome.
    Marland JR; Smillie KJ; Cousin MA
    PLoS One; 2016; 11(1):e0147974. PubMed ID: 26808141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Temporal and brain region-specific elevations of soluble Amyloid-β
    Tallino S; Winslow W; Bartholomew SK; Velazquez R
    Aging Cell; 2022 Apr; 21(4):e13590. PubMed ID: 35290711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
    Heller HC; Salehi A; Chuluun B; Das D; Lin B; Moghadam S; Garner CC; Colas D
    Neurobiol Learn Mem; 2014 Dec; 116():162-71. PubMed ID: 25463650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circadian rhythms of cardiovascular functions are modulated by the baroreflex and the autonomic nervous system in the rat.
    Makino M; Hayashi H; Takezawa H; Hirai M; Saito H; Ebihara S
    Circulation; 1997 Sep; 96(5):1667-74. PubMed ID: 9315563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome.
    Hampton TG; Stasko MR; Kale A; Amende I; Costa AC
    Physiol Behav; 2004 Sep; 82(2-3):381-9. PubMed ID: 15276802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxidant production and SOD1 protein expression in single skeletal myofibers from Down syndrome mice.
    Cowley PM; Nair DR; DeRuisseau LR; Keslacy S; Atalay M; DeRuisseau KC
    Redox Biol; 2017 Oct; 13():421-425. PubMed ID: 28697486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome.
    Mitra A; Blank M; Madison DV
    Brain Res; 2012 Feb; 1440():1-8. PubMed ID: 22284618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn.
    Kida E; Rabe A; Walus M; Albertini G; Golabek AA
    Exp Neurol; 2013 Feb; 240():178-89. PubMed ID: 23201095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circadian locomotor rhythms are normal in Ts65Dn "Down syndrome" mice and unaffected by pentylenetetrazole.
    Ruby NF; Fernandez F; Zhang P; Klima J; Heller HC; Garner CC
    J Biol Rhythms; 2010 Feb; 25(1):63-6. PubMed ID: 20075302
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pattern of congenital heart defects arising from reduced Tbx5 expression is altered in a Down syndrome mouse model.
    Polk RC; Gergics P; Steimle JD; Li H; Moskowitz IP; Camper SA; Reeves RH
    BMC Dev Biol; 2015 Jul; 15():30. PubMed ID: 26208718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. G-protein-associated signal transduction processes are restored after postweaning environmental enrichment in Ts65Dn, a Down syndrome mouse model.
    Baamonde C; Martínez-Cué C; Flórez J; Dierssen M
    Dev Neurosci; 2011; 33(5):442-50. PubMed ID: 21865666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.
    Parrini M; Ghezzi D; Deidda G; Medrihan L; Castroflorio E; Alberti M; Baldelli P; Cancedda L; Contestabile A
    Sci Rep; 2017 Dec; 7(1):16825. PubMed ID: 29203796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
    Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
    Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.